Azenta Life Sciences and Form Bio Partner to Support AAV Gene Therapy Development
Wednesday, May 14, 2025
Azenta Life Sciences has announced a strategic partnership between its GENEWIZ division and Form Bio, an artificial intelligence (AI) life sciences technology company. The collaboration aims to support the development of adeno-associated virus (AAV) gene therapies by offering an integrated solution that combines sequencing and advanced data analysis.
This partnership brings together GENEWIZ’s next-generation sequencing services for AAV applications with Form Bio’s AI-powered analysis tools. By combining these capabilities, gene therapy developers can gain better insight into AAV capsid contents, supporting improvements in safety, effectiveness, and production quality.
As part of the collaboration, GENEWIZ will offer synthesis and packaging of transgene expression cassettes along with high-quality long-read sequencing. Form Bio will use its Long-read AAV Analysis (LAAVA) software to assess AAV genome integrity, identify possible improvements in vector safety, and provide detailed reports to guide development. Together, these services create a simplified and efficient process that supports faster and more cost-effective progress from early development to lead candidate selection.
Source: prnewswire.com
